MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, which traded on Nasdaq under the ticker HLXA, is a clinical-stage biopharmaceutical company focused on developing antibody therapies for inflammatory diseases, including its lead candidate sonelokimab, a nanobody targeting both IL-17A and IL-17F. The company entered public markets through a SPAC business combination that closed in early 2022, and filed a Form 10-Q with the SEC on May 16, 2022, marking one of its first quarterly disclosures as a public entity. Operating squarely within the immunology and specialty biopharmaceutical sector, MoonLake was advancing its pipeline across dermatological and musculoskeletal indications at the time of the filing. Sign up at SpacDesk for full transaction history, sponsor data, and ongoing SEC filing coverage on MoonLake Immunotherapeutics.